title: Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings
source: Yahoo
date: 2025-10-08
url: https://finnhub.io/api/news?id=4222835e405c672e97b2d5ef9e8bc676ddc39cdc39fdafa5fb4cb7dc23c73cd8
Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.
